Advertisement
Canada markets closed
  • S&P/TSX

    22,290.62
    +31.15 (+0.14%)
     
  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     
  • DOW

    38,884.26
    +31.99 (+0.08%)
     
  • CAD/USD

    0.7282
    -0.0005 (-0.06%)
     
  • CRUDE OIL

    78.34
    -0.04 (-0.05%)
     
  • Bitcoin CAD

    85,740.62
    -1,255.27 (-1.44%)
     
  • CMC Crypto 200

    1,292.74
    -72.38 (-5.30%)
     
  • GOLD FUTURES

    2,322.90
    -1.30 (-0.06%)
     
  • RUSSELL 2000

    2,064.65
    +3.97 (+0.19%)
     
  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     
  • NASDAQ futures

    18,203.50
    +4.00 (+0.02%)
     
  • VOLATILITY

    13.23
    -0.26 (-1.93%)
     
  • FTSE

    8,313.67
    +100.18 (+1.22%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6771
    0.0000 (0.00%)
     

How Did Novo Nordisk’s Modern Insulin Segment Perform in 3Q17?

In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.